Calluna Pharma AS

Quick facts

Phase 2 pipeline

• CAL101 · Oncology
  CAL101 is a phosphatidylinositol 3-kinase (PI3K) delta inhibitor that selectively blocks PI3K signaling in immune cells to modulate immune responses.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Calluna Pharma AS portfolio CI brief
• Calluna Pharma AS pipeline updates RSS